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Abstract
Background In human TKA studies, intraosseous regio-
nal administration (IORA) of prophylactic antibiotics
achieves local tissue antibiotic concentrations 10 times
greater than systemic administration. However, it is unclear
if such high concentrations provide more effective
prophylaxis.
Questions/purposes We asked: (1) What prophylaxis
dosage and route (intravenous [IV] versus IORA of pro-
phylactic antibiotics) produce less in vivo bacterial burden
compared with no-antibiotic controls? (2) Compared with
controls, what prophylaxis dosage and route yield fewer
colony-forming units (CFUs) in euthanized animals in a
model of TKA? (3) Is prophylactic IORA of antibiotics
more effective than same-dose IV antibiotic administration
in reducing CFUs?
Methods Mice (six to nine per group) were block ran-
domized to one of six prophylaxis regimens: control,
systemic cefazolin (C100IV), IORA of cefazolin
(C100IORA), systemic vancomycin (V110IV), low-dose
systemic vancomycin (V25IV), and low-dose IORA of
vancomycin (V25IORA). Surgery involved placement of an
intraarticular knee prosthesis, followed by an inoculum of
bioluminescent Staphylococcus aureus strain Xen36. Bio-
photonic imaging assessed in vivo bacterial loads, and after
4 days bacterial load was quantified using culture-based
techniques. Comparisons were made for each prophylactic
regimen to controls and between same-dose IV and IORA
of prophylactic antibiotic regimens.
Results Mice treated with systemic high-dose van-
comycin, IORA of vancomycin, or IORA of cefazolin had
lower in vivo Staphylococcus aureus burdens (median area
under curve, Control: 5.0 9 106; V110IV: 1.5 9 10
6, dif-
ference of medians 3.5 9 106, p = 0.003; V25IV:
1.94 9 106, difference 3.07 9 106, p = 0.49; V25IORA:
1.51 9 106, difference 3.5 9 106, p = 0.0011; C100IORA:
1.55 9 106, difference 3.46 9 106, p = 0.0016; C100IV:
2.35 9 106, difference 2.66 9 106, p = 0.23.) Similar
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findings were seen with culture-based techniques on
recovered implants. IORA of prophylactic antibiotics was
more effective than same-dose IV administration in
reducing bacterial load on recovered implants (median
CFUs\ 7.0 9 100 vs 2.83 9 102, p = 0.0183).
Conclusions IORA of prophylactic cefazolin and van-
comycin was more effective than the same dose of
antibiotic given systemically. The effectiveness of van-
comycin in particular was enhanced by IORA of
prophylactic antibiotics despite using a lower dose.
Clinical relevance Our study supports previous studies of
IORA of prophylactic antibiotics in humans and suggests
this novel form of administration has the potential to
enhance the effectiveness of prophylaxis in TKA. Because
of concerns regarding antibiotic stewardship, IORA of
prophylactic vancomycin may be more appropriately
restricted to patients having TKA who are at greater risk of
infection, and clinical trials are in progress.
Introduction
Prophylactic antibiotics aim to provide protection against
the bacteria most likely to cause contamination during
surgery [5, 57]. The two most common bacteria causing
contamination and subsequent deep infection in TKAs are
Staphylococcus aureus and coagulase-negative staphylo-
cocci [14, 26, 37]. In the 1960s and 1970s when
preoperative prophylactic antibiotics were introduced, as
much as 98% of hospital isolates of coagulase-negative
staphylococci and 97% of S aureus were sensitive to
cephalosporins [18, 27, 33, 42], and cephalosporins sub-
sequently became the commonly recommended agent for
prophylaxis in arthroplasty [7, 11, 23, 25]. Currently
however, as much as 90% of hospital coagulase-negative
staphylococci isolates are resistant to cephalosporins [14,
26, 37, 50, 55], and 30% to 56% of S aureus cultured from
infected joint arthroplasties are methicillin-resistant
(MRSA) [30, 31, 34, 39]. Vancomycin has been suggested
as an alternative prophylactic agent, as currently it remains
effective against MRSA and coagulase-negative staphylo-
cocci resistant to cefazolin [4, 49]. However injudicious
use of vancomycin may risk further resistance, and in
clinical studies it is a less-effective prophylactic agent than
cefazolin against methicillin-sensitive S aureus strains
(MSSA) [4, 19]. This may be because adequate van-
comycin tissue levels are not achieved with typical
systemic doses [22, 42], particularly when timing of pro-
phylactic administration is suboptimal [4, 17].
Higher tissue levels of antibiotic can be achieved with
alternative methods of administration. Intraosseous regio-
nal administration (IORA) of prophylactic antibiotics is a
novel form of administration that involves intraosseous
injection after tourniquet inflation but before skin incision.
In a randomized trial of patients who had TKAs comparing
1g cefazolin given by IORA or systemic routes, IORA
achieved 10 times greater antibiotic tissue concentrations
[57]. IORA also achieves high tissue concentrations when
lower doses of prophylactic antibiotic are used [56], an
advantage for agents such as vancomycin where systemic
toxicity including red man syndrome is a concern [9].
However it is unclear if these high tissue concentrations
seen in clinical studies of IORA using either vancomycin
or cefazolin provide more effective prophylaxis against
infection.
The aim of our study was to compare the effectiveness
of prophylactic IORA of antibiotics with systemic admin-
istration using an in vivo murine model of TKA [38].
Specifically, we asked: (1) What antibiotic administration
dosage and route (intravenous [IV] versus IORA) produce
less in vivo bacterial burden compared with no-antibiotic
controls? (2) Compared with controls, what prophylactic
antibiotic administration dosage and route yield fewer
colony-forming units (CFUs) in euthanized animals in a
model of TKA? (3) Is prophylactic IORA more effective




Bioluminescent MSSA Xen36 [6] (Perkin Elmer, Waltham,
MA, USA) was used in all experiments. Xen36 is a
derivative of clinical bacteremia isolate ATCC 49525
(Wright) with a modified lux operon from Photorhabdus
luminescens stably integrated in a native plasmid [6].
Bacteria were grown overnight in Tryptic soy broth
(Fort Richard Laboratories Ltd, Auckland, New Zealand)
at 37 C with shaking at 200 rpm, then reinoculated in fresh
media at 1:5 and incubated for an additional 90 minutes.
Bacteria then were checked for light expression, washed
three times in phosphate-buffered saline (PBS), and
resuspended in PBS to obtain approximately 5 9 109 CFU/
mL. The concentration of bacteria in solution was verified
retrospectively by plating and culture.
Animals
Female CD1 mice were obtained from the specific patho-
gen-free breeding facility at the University of Auckland.
The mice were 7 to 9 weeks old on arrival and were given
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food and water ad libitum. Animals were housed and cared
for in accordance with the New Zealand Animal Welfare
Act [36] and institutional guidelines provided by the
University of Auckland Animal Ethics Committee, which
reviewed and approved these experiments under applica-
tion R1134. As single housing of animals is discouraged,
all experiments were performed using female mice, as they
are less aggressive than males, and so less likely to injure
themselves or each other when housed together. Conditions
and diet were identical for all animals. To minimize the
number of animals required, while accounting for any host,
bacterial, or surgical variation, one experiment was per-
formed using a block design (Fig. 1). Surgery was
performed on six separate occasions using a different
cohort of mice and a fresh preparation of bacteria. At each
surgery six to eight animals were randomized to one of the
six experimental groups, to give group sizes of six to eight
animals.
Antibiotic Prophylaxis
Mice were randomized into six experimental groups: (1) no
antibiotic prophylaxis (n = 7); (2) systemic vancomycin
(110 mg/kg, V110IV, n = 6); (3) systemic vancomycin (25
mg/kg, V25IV, n = 6); (4) intraosseous vancomycin (25 mg/
kg, V25IORA, n = 7); (5) intraosseous cefazolin (100 mg/kg,
C100IORA, n = 9); and (6) systemic cefazolin (100 mg/kg,
C100IV, n = 7). These experimental groups represent van-
comycin IV at either a high therapeutic dose (110 mg/kg)
or a suboptimal dose (25 mg/kg) or intraosseously at a low
dose (25 mg/kg). We administered cefazolin at a standard
therapeutic dose either IV or intraosseously. These reflect
the dosages and routes of administration used in two pre-
vious human studies of IORA [56, 57]. One mouse from
the IORA cefazolin (100 mg/kg) group and one from the
systemic vancomycin (25 mg/kg) group were euthanized
for losing more than 20% of baseline body weight per
Block Randomization 
7- to 9-week-old female CD1 mice 
n = 42 
Intraosseous vancomycin 
(25 mg/kg) 
n = 7 
Control 
(no antibiotics) 
n = 7 
Systemic vancomycin 
(110 mg/kg)  
n = 6 
Systemic vancomycin 
(25 mg/kg) 
n = 6 
Intraosseous cefazolin 
(100 mg/kg) 
n = 9 
Systemic cefazolin 
(100 mg/kg) 
n = 7 
110 mg/kg vancomycin 
via lateral tail vein 
injection 
25 mg/kg vancomycin via 
lateral tail vein injection 
25 mg/kg vancomycin via 
intraosseous injection 
proximal tibia 
100 mg/kg cefazolin via 
intraosseous injection 
proximal tibia 
100 mg/kg cefazolin  
via lateral tail vein 
injection 
0.6-mm K-wire was surgically placed in the distal femur 
protruding into the knee  
2-µL aliquot containing 5 x 106 CFU of S aureus Xen36 was 
inoculated in the knee before closure of surgical wound 
Biophotonic imaging at 24 hours, 48 hours, 72 hours, and 96 
hours after the procedure  
Mice were euthanized and bacterial counts enumerated from K-
wire and surrounding tissue by culture-based methods  
One mouse from the IORA cefazolin (100 
mg/kg) group and 1 mouse from the 
systemic vancomycin (25 mg/kg) group 
were excluded and euthanized for losing 
more than 20% of baseline body weight per 
institutional guidelines 
Fig. 1 A schematic of the experimental design we used in this study is shown.
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institutional guidelines and were excluded from the anal-
ysis (Fig. 1).
Antibiotics, when used, were administered either sys-
temically via an IV route or regionally (below a tourniquet)
via an intraosseous route. Systemic antibiotics were intro-
duced by injection into the lateral tail vein 30 minutes
before surgery. Regional intraosseous antibiotics, however,
were administered by direct injection into the proximal
tibia after tourniquet inflation to the extremity and imme-
diately before surgery. Antibiotics were given by
intraosseous injection into the tibia using a 26-gauge nee-
dle as previously described [24, 29, 47]. The 110 mg/kg
dose of vancomycin is an effective dose in mice, approx-
imating the area under the curve (AUC) of 400 mg.hour/L
for a typical human dose of vancomycin (1 g every 12
hours) [20, 38]. Using the body surface normalization
method [44], this represents a human dose of approxi-
mately 10 to 15 mg/kg. We used an IORA dose of
vancomycin that was approximately 25% of this, as
reported in a human study, where a lower dose was used to
protect against systemic effects such as red man syndrome
[56]. Because cefazolin has minimal systemic toxicity, we
used the same dose for the systemic and IORA routes as in
a previous IORA study of humans [57]. The cefazolin dose
of 100 mg/kg in mice gives serum concentrations similar to
a 1- to 2-g prophylactic dose in humans [8, 28, 54].
Surgical Procedure
Mice were weighed preoperatively and inhalational
isoflurane (3.0%) was administered for anesthesia. In the
absence of a toe pinch reflex, the right leg was depilated
using clippers and an above-knee tourniquet was applied.
The surgical site was prepared using an iodine-povidone
swab followed by an alcohol swab and a final iodine-
povidone wash.
The knee was accessed using a medial parapatellar
approach and the intercondylar region of the distal femur
identified. The femoral medullary canal was reamed man-
ually with sequentially larger-gauge needles for the
stainless steel implant, starting with a 26-gauge needle. A
sterile 0.6-mm K-wire then was inserted in a retrograde
fashion through the intercondylar region into the intrame-
dullary cavity of the distal femur. The K-wire was cut with
approximately 1 mm of wire protruding in the joint cavity.
Before closing, a 2-lL aliquot containing approximately
5 9 106 CFU of S aureus Xen36 was pipetted into the
joint. The patella complex then was reduced and the inci-
sion closed with 6–0 MonocrylTM sutures (Ethicon,
Somerville, NJ, USA). The total tourniquet time for each
mouse was 30 minutes. Postoperatively, the mice received
acetaminophen (paracetamol) (6 mg/mL) in the drinking
water and carprofen (5 mg/kg) subcutaneously once daily.
Biophotonic Imaging
Biophotonic imaging was used to noninvasively measure
the bioluminescent signal emitted by S aureus Xen36 from
anesthetized mice to provide information regarding the
localization of the bacterium (given as photons per second
per square centimeter per steradian [photons second/cm2/
sr]) (Fig. 2). We also quantified the bacterial burden
in vivo from the biophotonic signal of selected regions of
interest (given as photons/second) using Living Image
software (Perkin Elmer) (Fig. 3). Measurements were
obtained daily to present as values for the AUC for each
animal (Fig. 4).
Assessment of bioluminescence (photons/second/cm2/
sr) from living animals was measured after gaseous anes-
thesia with isoflurane using the IVIS1 Kinetic camera
system (Perkin Elmer). A photograph (reference image)
was taken under low illumination before quantification of
photons emitted from Xen36 at a binning of four over 5
minutes using the Living Image software. For anatomic
localization, a pseudocolor image representing light
intensity (blue, least intense to red, most intense) was
generated using the Living Image software and superim-
posed over the gray-scale reference image.
Bioluminescence in specific regions of individual mice also
was quantified using the region of interest tool in the
Living Image software program (given as photons per
second).
Quantification of Bacteria in the Knee and Implant
Mice were euthanized by cervical dislocation under anes-
thesia. The hindlimb was surface-sterilized with 70%
ethanol and the skin removed. The knee (including
approximately 5 mm of the proximal end of tibia and distal
end of femur) and surrounding tissue were excised. The K-
wire was extracted from the femur and placed in a 1.5-mL
microtube containing 0.5 mL PBS. The excised knee was
placed in a 2-mL sample tube containing ceramic beads
and 1 mL PBS and homogenized (3 9 10 seconds at 3.55
m/second) using a tissue disruptor (OMNI International,
Kennesaw, GA, USA). Serial dilutions were plated on
Mannitol salt agar (Fort Richard Laboratories Ltd) and
grown overnight at 37 C for viable count enumeration.
Plates subsequently were imaged with the IVIS1 Kinetic
camera system to confirm recovery of bioluminescent
S aureus Xen36.
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Statistics
Data analysis was performed using the GraphPad Prism
(V6) software package (GraphPad Software Inc, La Jolla,
CA, USA). Briefly, in vivo bacterial burdens (measured as
photons per second and calculated AUC values for each
animal) were compared between controls and each treat-
ment group using the Kruskal-Wallis test and Dunn’s post
hoc analysis. Ex vivo bacterial burdens from tissue samples
and implanted K-wires (measured as CFUs for each ani-
mal) were compared between controls and each treatment
group using the Kruskal-Wallis test and Dunn’s post hoc
analysis. Ex vivo bacterial burdens from tissue samples and
implanted K-wires also were compared between same dose
IV and IORA treatments using a two-tailed Mann Whitney
test. The number of animals with culture-positive or neg-
ative K-wires was compared using Fisher’s exact test
comparing same dose IV versus IORA treatment.
Fig. 2 Bioluminescence from S aureus Xen36 from anesthetized
animals was assessed after surgery. The images show peak biolumi-
nescence with variations in color representing light intensity at a
given location. Red represents the most intense light emission,
whereas blue corresponds to the weakest signal. The color bar
indicates relative signal intensity (as photons/second/cm2/steradian
[Sr]). Mice were imaged at various times after surgery with an
integration time of 5 minutes. One representative animal is shown for
each group. IV = intravenous; IORA = intraosseous regional
administration; V110IV = systemic vancomycin, 110 mg/kg; V25IV
= systemic vancomycin, 25 mg/kg; V25IORA = IORA vancomycin, 25
mg/kg; C100IORA = IORA cefazolin, 100 mg/kg; C100IV = systemic
cefazolin, 100 mg/kg.
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Results
Influence of Antibiotic Dosage and Route on Bacterial
Burden (Biophotonic Imaging)
Biophotonic imaging showed lower levels of biolumines-
cent bacteria in all vancomycin-treated animals as early as
1 day after surgery (Table 1)(median bioluminescence,
Control: 2.2 9 106 [range, 7.2 9 105–4.3 9 106]; V110IV:
4.9 9 105 [range, 2.5 9 105–7.2 9 105], difference of
median: 1.7 9 106, p = 0.0016; V25IV: 4.9 9 10
5 [range,
3.6 9 105–5.7 9 105], difference of medians: 1.7 9 106, p
= 0.0028; V25IORA: 5.3 9 10
5 [range, 4.73 9 105–
6.15 9 105], difference of medians: 1.7 9 106, p = 0.0148)
(Fig. 3A). With the numbers available, there was no dif-
ference in bioluminescence between untreated animals and
those treated with cefazolin (median bioluminescence,
Control: 2.2 9 106 [range, 7.15 9 105–4.34 9 106];
C100IORA: 6.2 9 10
5 [range, 4.1 9 105–1.1 9 106], p =
0.0606; C100IV: 6.1 9 10
5 [range, 3.68 9 105–
2.55 9 106], p = 0.2335) (Fig. 3A).
At 4 days after surgery, the bioluminescent signals from
animals treated with a suboptimal concentration of van-
comycin IV (V25IV) returned to near control levels.
However, the bioluminescent signals obtained from ani-
mals administered high-dose systemic IV vancomycin
(V110IV), low-dose regional intraosseous vancomycin
(V25IORA), and regional intraosseous cefazolin
(C100IORA), were lower than those from control animals at
this time (median bioluminescence (Table 2): Control:
1.64 9 106 [range, 7.76 9 105–3.96 9 106]; V110IV:
5.45 9 105 [range, 4.30 9 105–1.20 9 106], difference of
median: 1.10 9 106, p = 0.013; V25IV: 1.13 9 10
6 [range,
5.91 9 105–1.40 9 106], difference of median:
5.10 9 106, p [ 0.99; V25IORA: 5.14 9 10
5 [range,
3.83 9 105–8.96 9 105], difference of medians:
1.13 9 106, p = 0.0012; C100IORA: 6.18 9 10
5 [range,
3.88 9 105–1.17 9 106], difference of medians:
1.02 9 106, p = 0.0140; C100IV: 6.72 9 10
5 [range,
4.63 9 105–1.30 9 106], difference of medians:
Fig. 3A–B Quantification of bioluminescence from S aureus Xen36
from anesthetized animals after surgery is shown. The bioluminescent
signals originating from individual animals at (A) 1 day and (B) 4
days after surgery were obtained using the region of interest tool in
the Living Image software program (given as photons/second). The
dotted line represents the level of background from uninfected
animals. Median values per group are denoted by solid lines. Each
symbol represents an individual animal. Data are pooled from six
independent repeats with one to two animals per group per repeat. IV
= intravenous; IORA = intraosseous regional administration; V110IV
= systemic vancomycin, 110 mg/kg; V25IV = systemic vancomycin,
25 mg/kg; V25IORA = IORA vancomycin, 25 mg/kg; C100IORA =
IORA cefazolin, 100 mg/kg; C100IV = systemic cefazolin, 100 mg/kg.
Fig. 4 Area under curve values (summation during entire test period)
from bioluminescent signals obtained throughout the experiment are
shown. The dotted line represents the level of background from
uninfected animals. Median values per group are denoted by solid
lines. Each symbol represents an individual animal. Data are pooled
from six independent repeats with one to two animals per group per
repeat. IV = intravenous; IORA = intraosseous regional administra-
tion; V110IV = systemic vancomycin, 110 mg/kg; V25IV = systemic
vancomycin, 25 mg/kg; V25IORA = IORA vancomycin, 25 mg/kg;
C100IORA = IORA cefazolin, 100 mg/kg; C100IV = systemic
cefazolin, 100 mg/kg.
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9.68 9 105, p = 0.1015 (Fig. 3B). Likewise, AUC values
calculated for the bioluminescence signals from treated
mice throughout the experiment were approximately 1
.
4 the
value of those calculated for the untreated controls (median
bioluminescence (Table 3): Control: 5.01 9 106 [range,
3.30 9 106–1.02 9 107]; V110IV: 1.52 9 10
6 [range,
Table 1. Staphylococcus aureus bioluminescence Day 1 after surgery for antibiotic treatment compared with no treatment
Treatment Median (range)* Difference of medians to control* p value
Control 2.19 9 106 (7.15 9 105–4.34 9 106)
V110IV 4.90 9 10
5 (2.51 9 105–7.20 9 105) 1.70 9 106 0.0016
V25IV 4.94 9 10
5 (3.60 9 105–5.70 9 105) 1.70 9 106 0.0028
V25IORA 5.34 9 10
5 (4.73 9 105–6.15 9 105) 1.66 9 106 0.0148
C100IORA 6.21 9 10
5 (4.14 9 105–1.07 9 106) 1.57 9 106 0.0606
C100IV 6.06 9 10
5 (3.68 9 105–2.55 9 106) 1.58 9 106 0.2335
* Photons/second; C = cefazolin; V = vancomycin; IV = intravenous; IORA = intraosseous regional administration.
Table 2. Staphylococcus aureus bioluminescence 4 days after surgery for antibiotic treatment compared with no treatment
Treatment Median (range)* Difference of medians to control* p value
Control 1.64 9 106 (7.76 9 105–3.96 9 106)
V110IV 5.45 9 10
5 (4.30 9 105–1.20 9 106) 1.10 9 106 0.0126
V25IV 1.13 9 10
6 (5.91 9 105–1.40 9 106) 5.10 9 105 [ 0.9999
V25IORA 5.14 9 10
5 (3.83 9 105–8.96 9 105) 1.13 9 106 0.0012
C100IORA 6.18 9 10
5 (3.88 9 105–1.17 9 106) 1.02 9 106 0.0140
C100IV 6.72 9 10
5 (4.63 9 105–1.30 9 106) 9.68 9 105 0.1015
* Photons/second; C = cefazolin; V = vancomycin; IV = intravenous; IORA = intraosseous regional administration.
Table 3. Staphylococcus aureus bioluminescence area under curve values during 4 days for antibiotic treatment compared with no treatment
Treatment Median (range) Difference of medians to control p value
Control 5.01 9 106 (3.30 9 106–1.02 9 107)
V110IV 1.52 9 10
6 (9.93 9 105–3.13 9 106) 3.49 9 106 0.0026
V25IV 1.94 9 10
6 (1.75 9 106–3.35 9 106) 3.07 9 106 0.4934
V25IORA 1.51 9 10
6 (1.25 9 106–2.43 9 106) 3.50 9 106 0.0011
C100IORA 1.55 9 10
6 (1.19 9 106–2.35 9 106) 3.46 9 106 0.0016
C100IV 2.35 9 10
6 (1.44 9 106–4.16 9 106) 2.66 9 106 0.2312
V = vancomycin; C = cefazolin; IV = intravenous; IORA = intraosseous regional administration.
Table 4. Staphylococcus aureus recovered from implant 4 days after surgery* for effect of antibiotic treatment compared with no treatment
Treatment Median (range) Difference of medians to control p value
Control 1.03 9 104 (1.08 9 103–5.75 9 105)
V110IV 9.17 9 10
1 (\ 7.0 9 100–2.00 9 103) 1.02 9 104 0.0313
V25IV 4.96 9 10
2 (\ 7.0 9 100–2.13 9 103) 9.80 9 103 0.0905
V25IORA \ 7.0 9 10
0 (\ 7.0 9 100–4.08 9 103) 1.03 9 104 0.0013
C100IORA 8.85 9 10
0 (\ 7.0 9 100–6.17 9 102) 1.03 9 104 0.0020
C100IV 2.83 9 10
2 (1.67 9 101–1.62 9 104) 1.00 9 104 0.8858
CFU = colony forming units; V = vancomycin; C = cefazolin; IV = intravenous; IORA = intraosseous regional administration.
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9.93 9 105–3.13 9 106], difference of median: 3.49 9
106, p = 0.0026; V25IV: 1.94 9 10
6 [range, 1.75 9 106–
3.35 9 106], difference of median: 3.07 9 106, p = 0.4934;
V25IORA: 1.51 9 10
6 [range, 1.25 9 106–2.43 9 106],
difference of medians: 3.50 9 106, p = 0.0011; C100IORA:
1.55 9 106 [range, 1.19 9 106–2.35 9 106], difference of
medians: 3.46 9 106, p = 0.0016; C100IV: 2.35 9 10
6
[range, 1.44 9 106–4.16 9 106], difference of median:
2.66 9 106, p = 0.2312) (Fig. 4).
Influence of Antibiotic Dosage and Route on S aureus
Survival (CFU Counts)
Similar to data from biophotonic imaging, CFUs obtained
from the implanted K-wire were lower in the high-dose
systemic IV vancomycin, low-dose regional intraosseous
vancomycin, and regional intraosseous cefazolin groups
than controls (Table 4)(median CFUs, Control: 1.03 9 104
[range, 1.08 9 103–5.75 9 105]; V110IV: 9.17 9 10
1
[range, \ 7.0 9 100–2.00 9 103], difference of median:
1.02 9 104, p = 0.0313; V25IV: 4.96 9 10
2 [range, \
7.0 9 100–2.13 9 103], difference of median: 9.80 9 103,
p = 0.0905; V25IORA:\ 7.0 9 10
0 [range,\ 7.0 9 100–
4.08 9 103], difference of medians: 1.03 9 104, p =
0.0013; C100IORA: 8.85 9 10
0 [range, \ 7.0 9 100–
6.17 9 102], difference of medians: 1.03 9 104, p =
0.0020; C100IV: 2.83 9 10
2 [range, 1.67 9 101–
1.62 9 104], difference of median: 1.00 9 104, p =
0.8858) (Fig. 5).
Although bacteria were recovered from the tissues sur-
rounding the implant site for all but one animal, mice
treated with intraosseous vancomycin or cefazolin had
lower numbers (Table 5): (median CFUs, Control:
1.17 9 108 [range, 3.94 9 106–5.37 9 108]; V110IV:
1.86 9 106 [range, 9.59 9 103–2.60 9 107], difference of
median: 1.15 9 108, p = 0.1376; V25IV: 1.95 9 10
6
[range, 6.64 9 102–1.27 9 107], difference of median:
1.15 9 108, p = 0.0454; V25IORA: 4.92 9 10
3 [range,
1.16 9 102–8.69 9 106], difference of medians:
1.17 9 108, p = 0.0005; C100IORA: 4.23 9 10
5 [range,\
1.30 9 101–9.69 9 106] difference of medians:
1.17 9 108, p = 0.0049; C100IV: 7.67 9 10
6 [range,
1.82 9 106–1.63 9 108], difference of median:
1.09 9 108, p = 0.8699 (Fig. 5).
IORA versus Same-dose IV Antibiotic Administration
Overall, intraosseous antibiotic administration was more
effective at reducing the burden of contaminating bacteria
in the tissue than the same dose of antibiotic administered
IV (median CFUs, IV: 3.16 9 106 [range, 6.64 9 102–
1.63 9 108]; IORA: 5.43 9 104 [range, \ 1.30 9 101–
9.69 9 106] difference of medians: 3.11 9 106, p = 0.0163)
(Fig. 6A). Bacteria were recovered from the K-wires
implanted in only five of 14 IORA-treated animals com-
pared with 11 of 13 animals treated intravenously with the
same dose of antibiotic (Fisher’s exact p = 0.0183; median
CFUs, IV: 2.83 9 102 [range,\ 7.0 9 100–1.62 9 104];
IORA:\ 7.0 9 100 [range,\ 7.0 9 100–4.08 9 103] dif-
ference of medians: 2.76 9 102, p = 0.0073) (Fig. 6B).
Discussion
Prophylactic antibiotics reduce deep infection rates in
arthroplasty [13, 23]. To be effective, prophylactic
Fig. 5A–B Quantification of viable S aureus Xen36 after surgery is
shown. The mice were euthanized 96 hours after surgery for
quantification of bacteria remaining in the (A) knee and surrounding
tissue and (B) implanted K-wire. The dotted line represents the limits
of detection. Median values per group are denoted by solid lines. Each
symbol represents an individual animal. Data are pooled from six
independent repeats with one to two animals per group per repeat. IV
= intravenous; IORA = intraosseous regional administration; V110IV
= systemic vancomycin, 110 mg/kg; V25IV = systemic vancomycin,
25 mg/kg; V25IORA = IORA vancomycin, 25 mg/kg; C100IORA =
IORA cefazolin, 100 mg/kg; C100IV = systemic cefazolin, 100 mg/kg.
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antibiotics must have adequate tissue concentrations at the
operative site from the time of incision until the time of
closure [5]. As antibiotic resistance increases, systemic
administration of cephalosporins may no longer provide
adequate tissue concentrations against coagulase-negative
staphylococci and MRSA. IORA allows much higher tissue
concentrations to be achieved [56, 57], and the current
study showed that overall, IORA of cefazolin and van-
comycin provided more effective prophylaxis than the
same dose of antibiotic given systemically in a murine
model of TKA.
There are a number of limitations to this study. First,
although we attempted to use the equivalent antibiotic doses
and copy the clinical situation of an intraarticular implant, it
is unclear how well this model approximates the clinical
situation of TKAs in humans. However because clinical
TKA infection rates range between 0.86% and 2.5% [1, 3,
37, 41], animal models such as this remain the only practical
way to provide adequate power to compare differing pro-
phylaxis regimes. Second, we chose to investigate only
MSSA, because vancomycin is likely to be more effective
than cefazolin against coagulase-negative staphylococci
and MRSA strains resistant to cefazolin. Similar to previous
studies [38, 43], we used a relatively high inoculum of
bacteria to better discriminate between the effectiveness of
prophylactic regimes for the three endpoints used (in vivo
bioluminescence, ex vivo implant, and periarticular tissue
counts). This may differ from the clinical situation in TKA,
because although contamination occurs in most if not all
TKAs [12], the overall bacterial inoculum is likely to be
lower than used in this model. In addition, vancomycin has
a longer half-life than cefazolin which may have affected
the comparison between groups as we used only one pre-
operative dose. However clinical data suggest the
Table 5. Staphylococcus aureus* recovered from periprosthetic tissue 4 days after surgery for effect of antibiotic treatment compared with no
treatment
Treatment Median (range) Difference of medians to control p value
Control 1.17 9 108 (3.94 9 106–5.37 9 108)
V110IV 1.86 9 10
6 (9.59 9 103–2.60 9 107) 1.15 9 108 0.1376
V25IV 1.95 9 10
6 (6.64 9 102–1.27 9 107) 1.15 9 108 0.0454
V25IORA 4.92 9 10
3 (1.16 9 102–8.69 9 106) 1.17 9 108 0.0005
C100IORA 4.23 9 10
5 (\ 1.30 9 101–9.69 9 106) 1.17 9 108 0.0049
C100IV 7.67 9 10
6 (1.82 9 106–1.63 9 108) 1.09 9 108 0.8699
* Colony forming units; V = vancomycin; C = cefazolin; IV = intravenous; IORA – intraosseous regional administration.
Fig. 6A–B The effect of the delivery route of prophylactic treatment
on S aureus Xen36 survival is shown. Mice treated with either 25 mg/
kg vancomycin or 100 mg/kg cefazolin were euthanized 96 hours
after surgery for quantification of bacteria remaining in the (A) knee
and surrounding tissue and (B) implanted K-wire. The dotted line
represents the limits of detection. Median values are denoted by solid
lines. Each symbol represents an individual animal. Data are pooled
from six independent repeats. IV = systemic administration; IORA =
intraosseous regional administration.
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preoperative dose is the most important in providing pro-
phylaxis [15, 16, 21, 51], and the faster rate of drug
metabolism in the mouse means the effect of differing half-
lives is reduced [44]. Finally we used only female mice, as
male mice are more likely to fight and injure themselves or
other animals when group housed. In murine models female
mice generally are more resistant to the development of
bacterial infection [40], however previous studies using this
TKA model also have been single-sex studies [2, 38] and
male and female differences are not known.
We found in vivo bacterial burden 4 days after simu-
lated TKAs to be lower than that of controls in both IORA
groups (low-dose vancomycin and standard-dose cefa-
zolin), and also in the group given high-dose systemic
vancomycin. The rationale for using a low-dose of van-
comycin with IORA relates to the multiple disadvantages
of systemic vancomycin prophylaxis. Systemic van-
comycin requires a prolonged administration time to
prevent red man syndrome, a pruritic, erythematous rash
related to histamine release with rapid infusion [32, 48]. A
prophylactic dose of 1 g requires the infusion to be started a
minimum of 1 hour before surgery, which is difficult to
achieve in an arthroplasty practice [4]. Vancomycin also
can cause renal and other systemic toxicity [9, 32]. The use
of a lower, targeted vancomycin dose through IORA
optimizes timing of administration and reduces the risk of
such systemic toxic effects.
Similar to data from biophotonic imaging, bacterial
CFU counts from the implanted K-wire were lower than
those of controls in both IORA groups, and in the group
given high-dose systemic vancomycin. This suggests high
tissue concentrations of vancomycin in particular are
important in its efficacy as a prophylactic agent. The killing
power of vancomycin is proportional to the area under the
concentration versus time curve [45, 46]; thus, higher
concentrations are likely to enhance efficacy, as seen in our
study. Inadequate tissue concentrations have been impli-
cated as the reason why systemic vancomycin is less
effective than cephalosporins against MSSA [4, 42, 52].
Niska et al. [38] used a murine model of prophylaxis
against implant infection to investigate the efficacy of
varying doses of antibiotic. They found vancomycin to
have a narrower effective dose range than daptomycin or
tigecycline with a 110-mg/kg dose markedly more effec-
tive than a 10-mg/kg dose. Although estimation of
equivalent human and mouse dosages is imperfect, our
study supports the finding that the efficacy of vancomycin
as a prophylactic agent depends on achieving high tissue
concentrations. IORA vancomycin, which will achieve
high concentrations despite the lower dose, resulted in
lower bacterial counts and IORA vancomycin appeared at
least as effective as cefazolin for prophylaxis against
MSSA in our model. In clinical studies of prophylaxis in
arthroplasty, vancomycin performs less well against MSSA
than cephalosporins [4, 19]. It seems likely that the clinical
efficacy of vancomycin prophylaxis against MSSA will be
enhanced if higher tissue concentrations can be achieved.
We found the same doses of vancomycin and cefazolin
were more effective via IORA than an IV dose. Bacteri-
cidal activity of cefazolin normally is considered to be
concentration-independent, and once tissue levels are four
to five times the minimum inhibitory concentration, further
increases do not increase efficacy [10]. Therefore while
high tissue concentrations of cefazolin with IORA may
provide benefit against organisms with high minimum
inhibitory concentrations of cefazolin such as coagulase-
negative staphylococci [55], they would be expected to
have less effect on more-sensitive strains such as the
MSSA used in our study. However, these data are based on
animal models of treatment of established infections [31,
53], rather than models of prophylaxis such as ours in
which prevention of infection is the goal. Initiation of
bacterial killing is known to occur earlier with increasing
cefazolin concentrations [10], a factor likely to be more
important in prophylaxis where preventing initial bacterial
adherence and subsequent biofilm formation is required.
This may explain our finding of greater efficacy for IORA
cefazolin prophylaxis compared with systemic adminis-
tration of the same cefazolin dose.
IORA of prophylactic cefazolin and vancomycin was
more effective than the same dose of antibiotic given
systemically. The effectiveness of vancomycin in particular
was enhanced by IORA administration despite a lower
IORA dose, suggesting vancomycin is more effective
against MSSA when high tissue concentrations such as
with IORA are achieved. Further clinical studies are nee-
ded to identify any unforeseen complications with IORA
use, particularly with vancomycin. The use of a lower dose
and depot effect may reduce the risk of red man syndrome
on tourniquet deflation, and this complication has not yet
been seen in human studies of IORA vancomycin. Con-
cerns regarding antibiotic stewardship remain, and routine
use of vancomycin by any route may not be justified. IORA
vancomycin may be more appropriately limited to patients
at higher risk of infection, such as with revision proce-
dures, and in patients with a high BMI [35]. Future clinical
studies will focus on these areas.
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